Evidence map›Paper›PMID 30914707›Full record

Trial reportScientific reports2019

Synergy between the alteration in the N-terminal region of butyrylcholinesterase K variant and apolipoprotein E4 in late-onset Alzheimer's disease.

Jacek Jasiecki, Anna Limon-Sztencel, Monika Żuk, Magdalena Chmara, Dominik Cysewski, Janusz Limon, Bartosz Wasąg

Open access · goldAbstract readClinical Trial
In one paragraph

Trial report in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.1field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Butyrylcholinesterase-Protein Interactions in Human Serum.International journal of molecular sciences · 2021
    Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Jacek JasieckiFaculty of Pharmacy with Subfaculty of Laboratory Medicine, Medical University of Gdańsk, Gdańsk, Poland. jjasiecki@gumed.edu.pl.ORCID 0000-0001-8192-6486
Anna Limon-SztencelConsultant Psychiatry, St. Adalbert Hospital, Copernicus Gdańsk, Gdańsk, Poland.
Monika ŻukDepartment of Biology and Medical Genetics, Medical University of Gdańsk, Gdańsk, Poland.ORCID 0000-0003-3600-5578
Magdalena ChmaraDepartment of Biology and Medical Genetics, Medical University of Gdańsk, Gdańsk, Poland.ORCID 0000-0003-1430-8367
Dominik CysewskiMass Spectrometry Laboratory Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland.ORCID 0000-0001-6206-0672
Janusz LimonPolish Academy of Sciences, Gdańsk Branch, Gdańsk, Poland.
Bartosz WasągDepartment of Biology and Medical Genetics, Medical University of Gdańsk, Gdańsk, Poland. bwasag@gumed.edu.pl.ORCID 0000-0002-3634-7562
University Clinical Centre · PLGdańsk Medical University · PLInstitute of Biochemistry and Biophysics, Polish Academy of Sciences · PLPolish Academy of Sciences · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While the life expectancy of the population has increased, Alzheimer's disease (AD) has emerged as one of the greatest health problems of old age. AD is characterized by neuronal loss and cognitive decline. In the AD brain, there is a decrease in levels of acetylcholinesterase (AChE) and an increase in the levels of the related enzyme butyrylcholinesterase (BChE), that accumulate in plaques and tangles. Apolipoprotein E (ApoE) is a major cholesterol carrier and plays an important role in maintaining lipid homeostasis. APOE-ε4 constitutes the most important known genetic risk factor for late-onset AD. It has been proposed that the BCHE-K allele (Ala539Thr) acts in synergy with the APOE-ε4 allele to promote risk for AD. However, there is insufficient evidence to support a correlation. Most studies focused only on the coding regions of the genes. In this study, we analyzed sequence regions beyond the BCHE coding sequence. We found synergy between APOE-ε4 and SNPs localized in 5'UTR (rs1126680) and in intron 2 (rs55781031) of the BCHE-K allele (rs1803274) in 18% of patients with late-onset AD (n = 55). The results show that the coexistence of the APOE-ε4 allele and 3 SNPs in the BCHE gene is associated with a highly elevated risk of late-onset AD. SNP (rs1126680) in 5'UTR of the BCHE gene is located 32 nucleotides upstream of the 28 amino acid signal peptide. Mass spectrometry analysis of the BChE protein produced by SNP (rs1126680) showed that the mutation caused an in frame N-terminal extension of 41 amino acids of the BChE signal peptide. The resultant variant with a 69 amino acid signal peptide, designated N-BChE, may play a role in development of AD.

Indexed as

AllelesMutation, MissensePolymorphism, Single Nucleotide5' Untranslated RegionsAgedAged, 80 and overAlzheimer DiseaseAmino Acid SubstitutionApolipoprotein E4ButyrylcholinesteraseFemaleHumansIntronsMaleProtein Domains5' Untranslated RegionsApolipoprotein E4BCHE protein, humanButyrylcholinesterase

Identifiers

PMID30914707
PMCPMC6435664
OpenAlexW2923153987

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.